ReviewCNS drugs2009
Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- The use of antipsychotics in the treatment of catatonia: a systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.Drugs in R&D · 2015Pooled it
- Atypical Neuroleptic Malignant Syndrome Without Rigidity During Clozapine Titration: A Diagnostic Challenge.Cureus · 2026Article
- Case Report: Atypical neuroleptic malignant syndrome induced by paliperidone palmitate-diagnostic challenges and clinical considerations.Frontiers in psychiatry · 2026Article
- Neuroleptic Malignant Syndrome: A Case Report of the Oldest Man in Literature.Clinical case reports · 2025Article
- Three Episodes of Neuroleptic Malignant Syndrome With Risperidone: A Case Report and Literature Review.Case reports in psychiatry · 2025Article
- Neuroleptic Malignant Syndrome with Low Dose Lithium, Without Concomitant Antipsychotics.Indian journal of psychological medicine · 2023Article
- Loxapine in the Treatment of Manic and Psychotic Symptoms in an Individual Intolerant to Multiple Mood-Stabilizing and Antipsychotic Medications.Case reports in psychiatry · 2023Article
- Serotonin Syndrome Triggered by Increasing the Dose of Quetiapine.Clinical practice and cases in emergency medicine · 2021Article
- Creutzfeldt-Jakob disease with neuroleptic malignant syndrome.Clinical case reports · 2021Article
- Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil.Noro psikiyatri arsivi · 2021Article
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
- Management of common adverse effects of antipsychotic medications.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- Diagnostic, Treatment, and System Challenges in the Management of Recurrent Neuroleptic Malignant Syndrome on a General Medical Service.Case reports in psychiatry · 2018Article
- Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up.Frontiers in psychiatry · 2018Article
- Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association.BJPsych bulletin · 2017Article
- Atypical Neuroleptic Malignant Syndrome Associated with Use of Clozapine.Case reports in emergency medicine · 2017Article
- Neuroleptic Malignant Syndrome Associated with Lithium Toxicity.Oman medical journal · 2016Article
- Psychotropic drug-associated electrocardiographic presentation of diffuse J-waves in hypothermia: case report and literature review.Heart and vessels · 2016Review
- Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality.Neurocritical care · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially severe idiosyncratic adverse reaction usually seen in the context of treatment with antipsychotic drugs. Although NMS is historically associated with the classic or 'typical' antipsychotic drugs, it is also a potential adverse effect of atypical antipsychotic drugs. The widespread use of atypical antipsychotic drugs highlights the need to examine the data relating to the symptomatology, diagnosis, classification and management of NMS with these newer agents. We used MEDLINE and EMBASE to identify NMS case reports and systematic reviews published to June 2008 related to the atypical antipsychotic drugs clozapine, olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride and quetiapine. Case reports and reviews were systematically examined. Our review suggests that, in general, NMS associated with atypical antipsychotic drugs manifests in a typical manner. One notable exception is clozapine-induced NMS, which appears less likely to manifest with extrapyramidal features, including rigidity and tremor. The available literature highlights the divergence of opinion relating to the core diagnostic features of NMS and its conceptualization as a categorical versus dimensional disorder. Both these issues have relevance for the identification of atypical or milder forms of NMS, which are sometimes seen with atypical antipsychotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.